Astrazeneca (AZN) Invested Capital (2009 - 2026)

Astrazeneca's Invested Capital history runs 18 years deep, the most recent figure standing at $32.2 billion for Q2 2026.

• In Q2 2026, Invested Capital fell 1.83% year-over-year to $32.2 billion; the TTM figure through Jun 2026 stood at $12.7 billion (up 68.19% YoY), while the FY2025 annual figure was $29.6 billion, down 2.22% from the prior year.
• Invested Capital for Q2 2026 stood at $32.2 billion, up from -$24.5 billion in the prior quarter.
• The five-year high for Invested Capital was $33.5 billion in Q2 2024, with the low at -$28.9 billion in Q3 2024.
• The 5-year median for Invested Capital is $3.2 billion (2023), against an average of $2.4 billion.
• Peak annual rise in Invested Capital reached 18.41% in 2022, while the deepest fall reached 104.14% in 2022.
• Astrazeneca's Invested Capital stood at $29.2 billion in 2022, then slipped by 2.09% to $28.6 billion in 2023, then gained by 5.85% to $30.3 billion in 2024, then slipped by 2.22% to $29.6 billion in 2025, then increased by 8.83% to $32.2 billion in 2026.
• Business Quant data shows AZN's Invested Capital at $32.2 billion in Q2 2026, -$24.5 billion in Q1 2026, and $29.6 billion in Q4 2025.